Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2018

01-11-2018 | Original Article

Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis

Authors: Ke Chen, Wenming Zhang, Zhaozhen Zhang, Yiping He, Yuan Liu, Xiujiang Yang

Published in: Digestive Diseases and Sciences | Issue 11/2018

Login to get access

Abstract

Background and Aim

Vascularity is a critical feature in the evaluation of pancreatic neuroendocrine tumor (PNET). When done by EUS, contrast agents are recommended. However, vascular architecture (VA) can also be evaluated by routine Doppler flow in EUS without contrast agents. Our aim was to provide a simple VA classification in EUS for PNET grade and prognosis.

Methods

All pathologically proven PNET cases with EUS between 2012 and 2018 were retrospectively analyzed. The Doppler imaging was retrieved for VA classification. Predictive model construction was performed by machine learning algorithms.

Results

A total of 112 PNET cases were evaluated, among which 93 cases were subjected to VA classification. The VA was classified into type A (peritumoral with or without intratumoral vessels [A1 or A2]); type B (only intratumoral vessels); and type C (flow was absent). The VA classification was significantly correlated with tumor grades: 74% type A1 was G1, 73% type B was G2, and 58% type C was G3. Multivariate analysis indicated that elevated serum CA19-9 and type C classification were the independent predictors of G3 tumor. Five machine learning models were constructed, among which random forest was the best one with an AUC of 0.9972. Low-risk patients classified by this model exhibited better prognosis than high-risk patients (p = 0.0087).

Conclusions

In the novel simple VA classification, peritumoral, intratumoral, and absent vessels are prone to be G1, G2, and G3, respectively. Combined with serum CA19-9 and lesion size, the VA classification could predict tumor grade and prognosis in PNET.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adil MT, Nagaraja R, Varma V, et al. A single centre analysis of clinical characteristics and treatment of endocrine pancreatic tumours. Int J Surg Oncol. 2015;2015:538948.PubMedPubMedCentral Adil MT, Nagaraja R, Varma V, et al. A single centre analysis of clinical characteristics and treatment of endocrine pancreatic tumours. Int J Surg Oncol. 2015;2015:538948.PubMedPubMedCentral
2.
go back to reference Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.CrossRef Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.CrossRef
3.
go back to reference Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine. 2012;41:40–52.CrossRef Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine. 2012;41:40–52.CrossRef
4.
go back to reference Deng B-Y, Liu F, Yin S-N, et al. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: a comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol. 2018;42:261–268.CrossRef Deng B-Y, Liu F, Yin S-N, et al. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: a comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol. 2018;42:261–268.CrossRef
5.
go back to reference Kloppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med. 2017;33:324–330.CrossRef Kloppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med. 2017;33:324–330.CrossRef
6.
go back to reference Han X, Xu X, Ma H, et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect. 2018;7:355–363.CrossRef Han X, Xu X, Ma H, et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect. 2018;7:355–363.CrossRef
7.
go back to reference Lotfalizadeh E, Ronot M, Wagner M, et al. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol. 2017;27:1748–1759.CrossRef Lotfalizadeh E, Ronot M, Wagner M, et al. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol. 2017;27:1748–1759.CrossRef
8.
go back to reference Kang J, Ryu JK, Son JH, et al. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm. J Gastroenterol Hepatol. 2018. Kang J, Ryu JK, Son JH, et al. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm. J Gastroenterol Hepatol. 2018.
9.
go back to reference De Robertis R, Cingarlini S, Tinazzi Martini P, et al. Pancreatic neuroendocrine neoplasms: magnetic resonance imaging features according to grade and stage. World J Gastroenterol. 2017;23:275–285.CrossRef De Robertis R, Cingarlini S, Tinazzi Martini P, et al. Pancreatic neuroendocrine neoplasms: magnetic resonance imaging features according to grade and stage. World J Gastroenterol. 2017;23:275–285.CrossRef
10.
go back to reference Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73:691–696.CrossRef Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73:691–696.CrossRef
11.
go back to reference Puli SR, Kalva N, Bechtold ML, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis[J]. World J Gastroenterol. 2013;19:3678–3684.CrossRef Puli SR, Kalva N, Bechtold ML, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis[J]. World J Gastroenterol. 2013;19:3678–3684.CrossRef
12.
go back to reference James PD, Tsolakis AV, Zhang M, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81:848–856.CrossRef James PD, Tsolakis AV, Zhang M, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81:848–856.CrossRef
13.
go back to reference Fujimori N, Osoegawa T, Lee L, et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2016;51:245–252.CrossRef Fujimori N, Osoegawa T, Lee L, et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2016;51:245–252.CrossRef
14.
go back to reference Palazzo M, Napoléon B, Gincul R, et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). Gastrointest Endosc. 2018;87:1481–1488.CrossRef Palazzo M, Napoléon B, Gincul R, et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). Gastrointest Endosc. 2018;87:1481–1488.CrossRef
15.
go back to reference Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71:951–959.CrossRef Ishikawa T, Itoh A, Kawashima H, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 2010;71:951–959.CrossRef
16.
go back to reference Iordache S, Angelescu R, Filip MM, et al. Power Doppler endoscopic ultrasound for the assessment of pancreatic neuroendocrine tumors. Endosc Ultrasound. 2012;1:150–155.CrossRef Iordache S, Angelescu R, Filip MM, et al. Power Doppler endoscopic ultrasound for the assessment of pancreatic neuroendocrine tumors. Endosc Ultrasound. 2012;1:150–155.CrossRef
17.
go back to reference Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–1193.CrossRef Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–1193.CrossRef
18.
go back to reference Lv Y, Han X, Zhang C, et al. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr Connect. 2018;7:169–178.CrossRef Lv Y, Han X, Zhang C, et al. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr Connect. 2018;7:169–178.CrossRef
19.
go back to reference Hijioka M, Ito T, Igarashi H, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464–1471.CrossRef Hijioka M, Ito T, Igarashi H, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464–1471.CrossRef
20.
go back to reference Hallemeier CL, Botros M, Corsini MM, et al. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011;34:567–572.CrossRef Hallemeier CL, Botros M, Corsini MM, et al. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011;34:567–572.CrossRef
21.
go back to reference Luo G, Jin K, Cheng H, et al. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett. 2017;14:6795–6800.CrossRef Luo G, Jin K, Cheng H, et al. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett. 2017;14:6795–6800.CrossRef
22.
go back to reference Konukiewitz B, Jesinghaus M, Steiger K, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol. 2018. Konukiewitz B, Jesinghaus M, Steiger K, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol. 2018.
Metadata
Title
Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis
Authors
Ke Chen
Wenming Zhang
Zhaozhen Zhang
Yiping He
Yuan Liu
Xiujiang Yang
Publication date
01-11-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5240-z

Other articles of this Issue 11/2018

Digestive Diseases and Sciences 11/2018 Go to the issue